GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InnoCan Pharma Corp (FRA:IP4) » Definitions » Capital Expenditure

InnoCan Pharma (FRA:IP4) Capital Expenditure : €-0.02 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is InnoCan Pharma Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

InnoCan Pharma's cash flow for capital expenditures for the three months ended in Sep. 2024 was €-0.01 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.02 Mil.

InnoCan Pharma Capital Expenditure Historical Data

The historical data trend for InnoCan Pharma's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCan Pharma Capital Expenditure Chart

InnoCan Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capital Expenditure
Get a 7-Day Free Trial -0.01 - -0.04 -0.03 -0.04

InnoCan Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.01 - - -0.01

InnoCan Pharma Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCan Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InnoCan Pharma Corp (FRA:IP4) » Definitions » Capital Expenditure
Comparable Companies
TSXV:LOVE TSX:CRDL TSXV:RX XCNQ:GRIN TSXV:ZYUS TSX:CPH TSXV:DB XCNQ:JUSH XCNQ:AYR.A XCNQ:HUGE ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
INNPF:USA INNO:Canada
Address
1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
Website
https://www.innocanpharma.com
InnoCan Pharma Corp is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. Geographically, it derives a majority of its revenue from the United States.

InnoCan Pharma Headlines

No Headlines